GSK Investigational Site

Tübingen, Baden-Wurttemberg 72076

0 studies enrolling now · 24 studies all time

What they study most

Alzheimer's Disease, Cirrhosis, Liver, Cystic Fibrosis, Giant Cell Arteritis, Herpes Zoster, Herpes Zoster Vaccine, Influenza, Lung Cancer, Non-Small Cell, Macular Degeneration, Melanoma, Myasthaenia Gravis, Neoplasms, Breast

Studies at this site

• Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer — Stopped early
• A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor — Stopped early
• Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies. — Completed
• Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older — Completed
• A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma — Completed
• A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022 — Completed
• Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older — Completed
• Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis — Stopped early
• Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma — Stopped early
• Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A) — Completed
• Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older — Completed
• Belimumab in Remission of VASculitis — Completed
• GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma — Completed
• Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration — Completed
• Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects — Completed
• A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease — Completed
• 28 Day Repeat Dose in Cystic Fibrosis Patients — Completed
• Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers — Stopped early
• Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers — Stopped early
• Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease — Completed
• Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease — Completed
• The Evaluation of Belimumab in Myasthenia Gravis (MG) — Completed
• Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer — Stopped early
• Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer — Completed